El­e­vate­Bio and Affi­ni-T part­ner on KRAS ther­a­pies; Cas­ma rais­es $46M to drug the cell’s garbage dis­pos­al sys­tem

Affi­ni-T is the lat­est to sign on with El­e­vate­Bio, for­mer Alex­ion head David Hal­lal’s one-stop-shop for cell and gene ther­a­py man­u­fac­tur­ing. Affi­ni-T will use El­e­vate­Bio’s lentivi­ral vec­tor sys­tem to en­gi­neer cell ther­a­pies tar­get­ed at KRAS.

Affi­ni-T and El­e­vate­Bio de­clined to dis­close any fi­nan­cial de­tails of the deal. Affi­ni-T launched out of Phil Green­berg’s work at Fred Hutch, and the biotech is tack­ling two KRAS dri­ver mu­ta­tions — G12V and G12D — with both pro­grams still in pre­clin­i­cal stages. In Ju­ly, Am­gen vet Dirk Nagors­en joined as the biotech’s CMO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER